- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02375737
Evaluating CVD Medication Adherence Program in Low SES (CVDMAT)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The investigators propose to evaluate the implementation of a medication adherence program among patients who attend Duke Outpatient Clinic (DOC). It is anticipated that, among the providers' patient panels, at least 100 and up to 300 with CVD risk and poor CVD medication adherence (<0.08 medication possession ratio) will consent to the program.
Using procedures from the investigators previous studies, the investigators will identify potential patients from the EHR, and will identify a pool of potential patients using electronic health records, with the goal of administering the program to at least 100 patients. Patients will be mailed letters, signed by their own provider or medical director of DOC, requesting their participation in the programs. The RA will contact patients via telephone to explain the study, screen for eligibility, and determine what mode of administration individuals prefer to receive the program (SMS, IVR, or email).
The primary outcome will be that the effectiveness/impact of the proposed adherence program will be a 10% improvement in MPR and CVD outcomes (anticipate reducing SBP by 5 mmHg, Hgb a1c by 0.5%, LDL-C by 20 mg/dl).
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27705
- Duke University Health System Clinic
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Medicaid recipient (preferred); however the investigators will include those patients with other types of insurance or those who are uninsured
- Enrolled in Duke Outpatient Clinic for at least one year
- Outpatient diagnostic code for hypertension and/or hypercholesterolemia and/or diabetes
- Poorly controlled BP levels (>140/90) and/or LDL-C (>130mg/dl) and/or HbA1c of >8 within last 6 months
Exclusion Criteria:
- No access to cell phone
- Not proficient in English
- Nursing home/long-term care facility resident or receiving home health care
- Impaired hearing/ speech/ vision
- Participating in another trial (pharmaceutical or behavioral)
- Planning to leave the area in the next 12 months
- Pregnancy (or planning)
- Diagnosis of life-threatening disease with death probable within 1 year
- Active Diagnosis of psychosis or dementia (has been hospitalized in the last 30 days)
- Diagnosis of ESRD
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: m-health
Patients will receive text message, emails, and monthly phone calls
|
Patients will receive e-reminders via text message and email.
A message library that allows us to disseminate constant and reliable information has been created.
Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence.
In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Adherence to the program's intervention
Délai: 6 months
|
It is measured as the proportion of technology or interventionist contacts responded to by a patient out of those received over the course of the intervention period.
This will be summarized descriptively by type of contact (technology vs. interventionist call) and subdivided by technology (SMS, email).
|
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Clinical effectiveness/impact of the program to pill refill adherence
Délai: 6 months
|
This will be measured by pulling pill refill records of those patients who are enrolled.
The investigators anticipate an improvement of 10% on pill refill adherence.
|
6 months
|
Clinical effectiveness/impact on BP
Délai: 6 months
|
This will be measured by assessing systolic BP values.
The investigators anticipate reducing SBP by 5 mmHg.
|
6 months
|
Clinical effectiveness/impact on A1C
Délai: 6 months
|
This will be measured by assessing A1C values.
The investigators anticipate reducing Hgb A1c by 0.5%.
|
6 months
|
Clinical effectiveness/impact on cholesterol
Délai: 6 months
|
This will be measured by assessing LDL-C levels in patients.
The goal is to reduce LDL-C levels by 20 mg/dl.
|
6 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Hayden Bosworth, PhD, Duke University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Pro00054572
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecrutementHypertension Essentielle | Hypertension, masquéTaïwan
-
University of Alabama at BirminghamTroy UniversityComplétéHypertension | Hypertension, résistante à la thérapie conventionnelle | Hypertension non contrôlée | Hypertension, blouse blancheÉtats-Unis
-
Vanderbilt University Medical CenterJohns Hopkins UniversityComplétéHypertension artérielle pulmonaire | Hypertension artérielle pulmonaire idiopathique | Hypertension artérielle pulmonaire associée | Hypertension artérielle pulmonaire héréditaireÉtats-Unis
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentInconnue
-
Centre Chirurgical Marie LannelongueInconnueHypertension pulmonaire thromboembolique chronique et hypertension artérielle pulmonaireFrance
-
Assistance Publique - Hôpitaux de ParisActif, ne recrute pasHypertension portale non cirrhotique intrahépatiqueFrance
-
AstraZenecaComplétéHypertension artérielle (hypertension).
-
University of South FloridaRetiréHypertension artérielle pulmonaire | Hypertension pulmonaire primitive familiale | Hypertension artérielle pulmonaire idiopathique | Hypertension pulmonaire primaireÉtats-Unis
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisInconnueHypertension artérielle pulmonaire (HTAP)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchComplétéHypertension artérielle pulmonaire idiopathiqueL'Autriche
Essais cliniques sur m-health
-
Florida State UniversityUniversity of North Carolina, Chapel Hill; University of GeorgiaInscription sur invitationRéduction du risque de maladies cardiovasculairesÉtats-Unis
-
IWK Health CentrePas encore de recrutement
-
Boston Children's HospitalUnited States Department of Defense; National Football LeagueComplétéCommotion cérébraleÉtats-Unis
-
Manan ShuklaComplétéAsthme | Maladie chroniqueÉtats-Unis
-
Noctrix Health, Inc.ComplétéSyndrome des jambes sans reposÉtats-Unis
-
Radicle ScienceComplétéDouleur abdominale | Digestion | Troubles gastro-intestinauxÉtats-Unis
-
Radicle ScienceRecrutementDouleur abdominale | Digestion | Troubles gastro-intestinauxÉtats-Unis
-
Radicle ScienceComplétéLa dépression | La douleur | Dormir | AnxiétéÉtats-Unis
-
Celero Systems, Inc.Recrutement
-
Virginia Commonwealth UniversityAgency for Healthcare Research and Quality (AHRQ)Complété